Search
Aceclofenac
go.drugbank.com/drugs/DB06736ApprovedIt is a more commonly prescribed drug in Europe. … It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670].
Mixtures: ZERODOL PCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesTrenibotulinumtoxinE
go.drugbank.com/drugs/DB19082Approved[L64118] It is the first and only rapid-onset, short-duration botulinum neurotoxin serotype E approved in Europe.[L64118] … and resolve within 2 to 3 weeks.
Synonyms: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001), BONTOXILYSIN-EInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalInclisiran is a long-acting, synthetic small interfering RNA (siRNA) directed against proprotein convertase subtilisin-kexin type 9 (PCSK9), which is a serine protease that regulates plasma low-density … lipoprotein cholesterol (LDL-C) levels.
Categories: Compounds used in a research, industrial, or household setting, Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) InhibitorsProducts: LYPTİMZİA 284 MG/1,5 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETBictegravir
go.drugbank.com/drugs/DB11799ApprovedInvestigationalIt has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677] … Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection.
Categories: MATE 1 Inhibitors, Cytochrome P-450 SubstratesOlcegepant
go.drugbank.com/drugs/DB04869InvestigationalOlcegepant is undergoing phase II trials in Europe and the US, with preliminary results suggesting that CGRP antagonists may represent a potential new approach to the treatment of migraine. … Boehringer Ingelheim Pharmaceuticals’ olcegepant (BIBN 4096) is a selective Calcitonin Gene-Related Peptide (CGRP) antagonist, a new class of drugs in development for the treatment of acute migraine attacks
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingBenserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalIn particular, although the specific levodopa/benserazide combination is formally approved for use in Canada and much of Europe, the FDA has approved another similar levodopa/dopa decarboxylase inhibitor … Moreover, the European Medcines Agency has conferred an orphan designation upon benseraside since 2015 for its potential to be used as a therapy for beta thalassaemia as well [F3].
Mixtures: MADOPAR®, MADOPAR®Categories: Aromatic L-amino Acid Decarboxylase InhibitorsBrexanolone
go.drugbank.com/drugs/DB11859ApprovedInvestigationalbrexanolone may also be undergoing clinical trials to investigate its abilities to treat super-refractory status epilepticus, it appears that some such studies have failed to meet primary endpoints that compare … The development and availability of brexanolone for the treatment of PPD in adult females subsequently provides a new and promising therapy where few existed before [F4066].
Categories: Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator, Neuroactive Steroid Gamma-Aminobutyric Acid (GABA) A Receptor Positive ModulatorsEdaravone
go.drugbank.com/drugs/DB12243ApprovedInvestigational[L44017] Edaravone was initially granted orphan designation by the European Medicines Agency on June 19, 2015 [L44007] and was under regulatory review in Europe. … Edaravone is a free radical scavenger and neuroprotective agent with antioxidant properties.[A254257] It has three tautomers.
Categories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household settingSynonyms: 1-phenyl-3-methyl-5-oxo-2-pyrazoline, 3-methyl-1-phenyl-2-pyrazolin-5-oneEmpagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart … [A203501] Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g.
Mixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGCategories: P-glycoprotein substrates, Sodium-Glucose Transporter 2 Inhibitors